Clinical TrialMajor Depressive Disorder (MDD)KetamineCompleted

Chart Review of Patients Undergoing Ketamine Treatments for Depression

Retrospective observational chart review (n=250) of outpatient induction-phase IV racemic ketamine for treatment-resistant major depressive disorder at a single Canadian centre.

Target Enrollment
250 participants
Study Type
observational
Design
Non-randomized

Detailed Description

This retrospective study reviews clinical charts from April 1, 2022 to June 29, 2025 to describe patient characteristics, treatment parameters, safety, and clinical outcomes following induction-phase intravenous racemic ketamine for treatment-resistant depression in a real-world outpatient centre.

Data include demographics, treatment course during the induction phase, adverse events, and prior neuromodulation history; sampling is non-probability and reflects routine clinical practice at the Ontario Ketamine and Infusion Centre.

Study Arms & Interventions

IV ketamine

experimental

Real-world outpatient induction-phase IV racemic ketamine treatments for TRD; chart-review cohort.

Interventions

  • Ketamine
    via IV• induction phase (real-world)

    Racemic IV ketamine at sub-anaesthetic doses per clinic protocol; repeated infusions during induction.

Participants

Ages
18 – 99
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • Age ≥ 18
  • Able to provide informed consent
  • Patient diagnosed with treatment-resistant depression
  • Outpatient recommended and approved by psychiatrist for ketamine treatment
  • Individuals who have previously received ECT, rTMS or any other neuromodulation can also receive ketamine

Exclusion Criteria

  • Exclusion Criteria:
  • History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist
  • Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment
  • History of substance misuse and/or dependence, including chronic alcohol abuse
  • Previous ketamine use
  • Acute dementia/delirium
  • Pregnancy/breastfeeding
  • Previous sensitivity to ketamine or related compounds
  • Unstable medical condition which may require anesthesia consult
  • History of elevated intracranial pressure or cerebrovascular accident
  • Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)

Study Details

Locations

Ontario Ketamine and Infusion Centre - Toronto Site — Mississauga, Ontario, Canada

Your Library